pclx-001
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 14, 2021 (NCT04836195)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Peptide N-myristoyltransferase 1INHIBITOR
NMT1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(NS(=O)(=O)c2c(Cl)cc(-c3ccnc(N4CCNCC4)c3)cc2Cl)c(CC(C)C)nn1C- Mol. weight
- 537.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3357685 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06613217 | Phase 1 | Oct 31, 2024 | Department of Defense, Ozmosis Research Inc., Pacylex Pharmaceuticals, University of Texas at Houston |
| NCT04836195 | Phase 1 | Sep 14, 2021 | Ozmosis Research Inc., Pacylex Pharmaceuticals, University of Alberta |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ozmosis Research Inc. | For profit | 2 | 0 | 1 | 2021 |
| Pacylex Pharmaceuticals | For profit | 2 | 2 | 1 | 2021 |
| Department of Defense | Government | 1 | 0 | 1 | 2024 |
| University of Alberta | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1